Clin Osteol 2012; 17(4): 136-142

Solitary bone plasmacytomaReview articles

T. Pika, J. Minařík, V. Prášil, H. Crháková, J. Bačovský, V. Ščudla

Solitary bone plasmacytoma (SBP) is a relatively uncommon entity from the group of monoclonal gammopathies. This is a solitary skeletal lesion made of monoclonal plasma cell populations, associated with bone involvement. Manifestation of the condition is fre­ quently associated with impaired function of the axial skeleton, neurological deficit and tenderness. Less frequently, this is a randomly detected asymptomatic bone lesion. The diagnosis is often complicated, requiring collaboration of many medical experts. If the dia­ gnosis of SBP is confirmed, the treatment modality is radiotherapy or, in case of structural instability or neurological involvement, sur­ gical therapy.

Keywords: solitary bone plasmacytoma, imaging methods, diagnosis

Published: December 11, 2012  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Pika T, Minařík J, Prášil V, Crháková H, Bačovský J, Ščudla V. Solitary bone plasmacytoma. Osteologický bulletin. 2012;17(4):136-142.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Dimopoulos MA, Moulopoulos LA, Maniatis A, Alexanian R. Solitary plas toma of bone and asymptomatic multiple myeloma. Blood 2000;96:2037-2044. Go to original source...
    2. Soutar R, Lucraft H, Jackson G, Reece A, Bird J, Low E, Samson D. Guidelines on the diagnosis and management of solitary plasmacytoma of extramedullary plasmacytoma. Br J Haematol 2004;124:717-726. Go to original source...
    3. Kyle RA, Rajkumar SV. Criteria for diagnosis, staging, risk stratification and r ponse assessment of multiple myeloma. Leukemia 2009;23:3-9. Go to original source...
    4. Bačovský J. Solitární plazmocytom. Interní Med 2005;10:444-446.
    5. Dores GM, Landgren O, McGlynn KA, Curtis RE, Linet MS, Devesa SS. Plasmacytoma of bone, extramedullary plasmacytoma, and multiple myeloma: in­ cidence and survival in the United States, 1992-2004. Br J Haematol 2008;144: 86-94. Go to original source...
    6. The International Myeloma Working Group. Criteria for the classification of mo­ noclonal gammopathies, multiple myeloma and related disorders: a report of International Myeloma Working Group. Br J Haematol 2003;121:749-757. Go to original source...
    7. Dingli D, Kyle RA, Rajkumar SV, Nowakowski GS, Larson DR, Bida JP, Gertz MA, Therneau TM, Melton LJ, Dispenzieri A, Katzmann JA Immunoglobulin free light chains and solitary plasmacytoma of bone. Blood 2006;108:1979-1983. Go to original source...
    8. Chargari C, Vennarini S, Servois V, Bonardel G, Lahutte M, Fourquet A, Bouscary D, Kirova YM. Place of modern imaging modalities for solitary plasmacytoma: Toward improved primary staging and treatment monitoring. Crit Rev Oncol Hematol 2012;82:150-158. Go to original source...
    9. Zamagni E, Nanni C, Patriarca F, Englaro E, Castelluci P, Geatti O et al. A pro­ spective comparison of 18F-Flurodeoxyglucose positron emission tomographycomputed tomography, magnetic resonance imaging and whole-body planar radi­ ographs in the assessment of bone disease in newly diagnosed multiple myeloma. Haematologica 2007;92:50-55. Go to original source...
    10. Adam Z, Bolcak K, Stanicek J, Buchler T, Pour L, Krejci M, Prasek J, Neubauer J, Vorlicek J, Hajek R. Fluorodeoxyglucose positron tomography in multiple my­ eloma, solitary plasmocytoma and monoclonal gammopathy of unknown signifi­ cance. Neoplasma 2007;54:536-540.
    11. Schirrmeister H, Buck AK, Bergmann L, Reske SN, Bommer M. Positron emissi­ on tomography (PET) for staging of solitary plasmacytoma. Cancer Biother Radiopharm 2003;18:841-845. Go to original source...
    12. Salaun P-Y, Gastinne T, Frampas E, Bodet-Milin C, Moreau P, Bodéré-Kraeber F. FDG-positron-emission tomography for staging and therapeutic assessment in pa­ tients with plasmacytoma. Haematologica 2008;93:1269-1271. Go to original source...
    13. Balleari E, Villa G, Garré S et al. Technetium-99m-sestaMIBI scintigraphy in tiple myeloma and related gammopathies: a useful tool for the identification and follow-up of myeloma bone disease. Haematologica 2001;86:78-84.
    14. Pinto AM, Califano C, Di Gennaro F, De Renzo A, Catalano L, J^ce L. Technetium-99m sestamibi scintigraphy in monitoring patients with multiple myeloma. Haematologica 2000;85:1000-1001.
    15. Knobel D, Zouhair A, Tsang RW et al. Prognostic factors in solitary plasm ma of bone: a multicenter Rare Cancer Network study. BMC Cancer 2006;6:118. Go to original source...
    16. Warsame R, Gertz MA, Lacy MQ et al. Trends and outcomes of modern staging of solitary plasmacytoma of bone. Am J Hematol 2012;87:647-651. Go to original source...
    17. Ramsingh G, Mehan P, Morgensztern D, Luo J, Vij R. Prognostic factors influ cing survival in solitary plasmacytoma. Br J Haematol 2009;145:533-550. Go to original source...
    18. Wilder RB, Ha CS, Cox JD, Weber D, Delasalle K, Alexanian R. Persistence of myeloma protein for more than one year after radiotherapy is an advers tic factor in solitary plasmacytoma of bone. Cancer 2002;94:1532-1537. Go to original source...
    19. Kumar S, Fonseca R, Dispenzieri A et al. Progno litary bone plasmacytoma. Blood 2003;101:1715-1717. Go to original source...
    20. Ozsahin M, Tsang RW, Poortmans P et al. Outcomes and patterns of failure in so­ litary plasmacytoma: a multicenter rare cancer J Radiation Oncology Biol Phys 2006;64:210-217. Go to original source...
    21. Liebross RH, Ha CS, Cox JD, Weber D, Delasalle K, Alexanian R. Solit plasmacytoma: outcome and prognostic factors following radiotherapy. Int J Radiation Oncology Biol Phys 1998;41:1063-1067. Go to original source...
    22. Tsang RW, Gospodarowicz MK, Pintilie M et al. Solitary plasmacytoma trea with radiotherapy: impact of tumor size on outcome. Int J Radiation Oncology Biol Phys 2001;50:113-120. Go to original source...
    23. Kumar S. Sol 2008;83:695-696.

    Return to the content


    Clinical Osteology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.